Tesamorelin reconstitution: how to mix it correctly

Last updated 2026-07-24

What is tesamorelin and why does reconstitution matter?

Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta (and the once-daily formulation Egrifta SV) for reduction of excess abdominal fat in HIV patients with lipodystrophy ^{[1] [2]}. It comes as a lyophilized (freeze-dried) powder in a vial because the peptide is not stable long-term in liquid form. You have to reconstitute it, meaning add sterile liquid back to the powder, before it can be drawn into a syringe and injected. This matters more than it sounds like it should. Get the reconstitution wrong (shake it too hard, use the wrong diluent, let it sit unrefrigerated) and you risk degrading the peptide before it ever reaches your bloodstream. The phase 3 trials that got tesamorelin approved used a specific reconstituted formulation dosed daily . Off-label users buying compounded tesamorelin are trying to replicate that same chemistry at home, so the mixing step is not a place to improvise. One honest caveat up front: this article covers the mechanics of reconstitution. It does not cover whether using tesamorelin outside its approved HIV-lipodystrophy indication is a good idea for you. The approval is narrow. Read tesamorelin for the full evidence picture before you decide anything.

How do you reconstitute tesamorelin step by step?

The general process below reflects standard peptide reconstitution technique described in orthopaedic and sports medicine literature on injectable peptide handling ^{[3] [4]}. Always defer to the specific product's own instructions for use, since exact diluent volumes differ by vial strength and manufacturer. 1. Wash your hands and wipe the top of both the tesamorelin vial and the bacteriostatic water vial with an alcohol swab. 2. Draw up the specified volume of bacteriostatic water into a syringe. 3. Insert the needle into the tesamorelin vial at an angle and let the water run down the inside glass wall. Do not shoot it directly onto the powder. 4. Let the vial sit for a minute, then gently swirl it in small circles. Do not shake it. 5. Keep swirling gently (or let it sit and swirl intermittently) until the powder is fully dissolved and the liquid looks clear, with no visible particles or cloudiness. 6. Label the vial with the date and time of reconstitution. 7. Refrigerate immediately. Swirling instead of shaking is not fussiness. Peptides are proteins, and proteins can denature (permanently lose their functional shape) under mechanical stress like vigorous agitation. A gentle swirl dissolves the powder without introducing that stress.

What do you mix tesamorelin with (bacteriostatic water vs sterile water)?

Bacteriostatic water is the standard diluent for tesamorelin reconstitution. It is sterile water with 0.9% benzyl alcohol added, and that benzyl alcohol acts as a preservative that inhibits bacterial growth in the vial across multiple uses ^[3]. Plain sterile water (without the preservative) has no antimicrobial protection once the vial is punctured. If you use it, most guidance treats the vial as single-use and requires the same-day discard, because there is nothing stopping bacterial growth after the seal is broken. Bacteriostatic water is why a reconstituted vial can be safely used across multiple injections over a period of days. Do not substitute regular tap water, saline you have around the house, or anything not labeled sterile and pharmaceutical grade. Reconstitution is one of the few steps in this whole process where there is genuinely no room for improvisation.

How much bacteriostatic water do you use for tesamorelin?

The exact volume depends on the vial's peptide content and the concentration you want to inject, and this varies by product and by the specific vial size a pharmacy or manufacturer dispenses. There is no single universal number that applies to every tesamorelin vial on the market. This is the single most common mistake in DIY reconstitution: assuming the volume from a forum post or a friend's protocol applies to your vial. It usually doesn't, because vial strengths differ. Always reconstitute according to the specific product's labeling or your prescribing provider's written instructions, and use the tesamorelin dosage calculator to check that your intended injection volume actually matches the dose your provider prescribed once the vial is mixed. Getting this math wrong in either direction matters. Too little diluent gives you an overly concentrated solution and makes small, accurate dosing hard. Too much diluent means you have to inject a larger volume to hit your target dose, which is just less comfortable and does nothing to help the mixing itself.

How long does reconstituted tesamorelin last, and how should it be stored?

For the FDA-approved Egrifta product, the manufacturer's labeling specifies a strict 24-hour window: once reconstituted, the vial must be used within 24 hours and refrigerated between 2°C and 8°C (36°F to 46°F) during that window, protected from light ^[2] . Any unused portion after 24 hours is discarded. That is a much shorter window than many other reconstituted peptides. This short shelf life is a direct consequence of the approved daily dosing regimen studied in the phase 3 trials, where patients reconstituted a fresh vial each day . It was never designed around multi-week vial reuse. Compounded tesamorelin products, made outside the FDA-approved manufacturing process, may carry different stated stability windows from the compounding pharmacy, sometimes longer, based on that pharmacy's own stability testing. If you are using a compounded product, follow that specific pharmacy's labeling, not the Egrifta package insert, since the formulations, buffers, and testing are not identical. General storage rules that apply regardless of source: keep the vial refrigerated, never freeze it, keep it out of direct light, and never use a vial that looks cloudy, discolored, or has particles floating in it after it was previously clear.

Why does tesamorelin need refrigeration after mixing?

Before reconstitution, lyophilized tesamorelin powder is relatively stable at controlled room temperature or refrigerated, per typical peptide storage guidance. After reconstitution, the peptide is dissolved in liquid, and that liquid environment is where degradation happens much faster. Heat accelerates the breakdown of the peptide chain, and repeated temperature swings (fridge to counter to fridge) stress it further. Refrigeration slows this degradation enough that the drug stays potent for its labeled window. It does not stop degradation entirely, which is exactly why there is a hard cutoff (24 hours for Egrifta) rather than an indefinite storage claim. Never leave a reconstituted vial out at room temperature between uses. If you are traveling, a small insulated cooler with an ice pack is the standard workaround, not a substitute for a real refrigerator once you're back.

How do you know if reconstituted tesamorelin has gone bad?

Visual inspection is your first check before every injection. The solution should be clear and colorless. If you see cloudiness, discoloration, or visible particles or clumps, do not inject it. That vial is compromised, regardless of how many hours are left in its stated window. Beyond visual inspection, there is no reliable at-home test for peptide potency. You cannot tell by smell or by how it feels going in whether the tesamorelin is still fully active; a degraded peptide can look perfectly clear and still have lost much of its biological activity. This is part of why the storage rules exist as hard limits rather than suggestions: by the time you'd notice a problem, you've likely already been under-dosing for a while. If a vial has been left out of the fridge for an extended period, has been shaken hard, or is past its labeled discard window, the safest and cheapest move is to discard it and reconstitute a fresh one. A wasted vial costs less than weeks of injecting an inactive peptide and wrongly concluding the drug doesn't work for you.

How is tesamorelin injected once it's reconstituted?

Tesamorelin is given by subcutaneous injection, meaning into the fat layer just under the skin, not into muscle. The approved dosing in the phase 3 trials that supported FDA approval was a daily subcutaneous injection, with the once-daily 2 mg formulation (Egrifta SV) developed later as a lower-volume alternative to the original reconstituted regimen ^{[1] [2]}. Common injection sites are the abdomen (rotated around the navel area, avoiding the navel itself) similar to how other subcutaneous peptides and insulin are injected. Rotating sites reduces the risk of local skin reactions and lumps (lipodystrophy) at a single overused spot, which is a documented consideration with repeated subcutaneous peptide dosing generally ^{[3] [4]}. Use a new sterile needle for every injection, even when drawing from the same reconstituted vial across multiple days. Reusing needles is a real infection risk and one of the easiest mistakes to eliminate entirely. For the specific injection volumes and daily amounts studied in trials, see tesamorelin dosage.

What equipment do you need to reconstitute and inject tesamorelin?

A minimal, complete kit looks like this: | Item | Purpose |

Does reconstitution differ between FDA-approved Egrifta and compounded tesamorelin?

Yes, in ways that matter for anyone comparing the two. Egrifta and Egrifta SV are manufactured under FDA oversight with a fixed, tested formulation, a specific labeled diluent volume, and a validated 24-hour post-reconstitution stability window backed by the manufacturer's own stability data submitted to FDA ^[2] . Compounded tesamorelin is prepared by a compounding pharmacy under section 503A or 503B of the Food, Drug and Cosmetic Act rather than through the standard new drug approval process ^[5]. Compounders can use bulk tesamorelin if it appears on FDA's applicable bulks list for that section ^{[6] [7]}, but compounded product is not the same FDA-reviewed formulation as Egrifta, and reconstitution instructions, diluent volumes, and stability claims can differ from pharmacy to pharmacy because each is generated by that pharmacy's own process, not a single approved label. This is not a reason to panic about compounded tesamorelin, but it is a reason to ask a compounding pharmacy directly for their specific reconstitution and stability data rather than assuming the Egrifta package insert applies to their product. If you want to understand what you're actually paying for across these options, see tesamorelin cost.

What mistakes ruin a tesamorelin reconstitution?

The failure modes are pretty consistent across peptide reconstitution generally, and tesamorelin is no exception: - Shaking instead of swirling. This is the single most common error and the easiest to avoid. Vigorous agitation can denature the protein.

• Injecting the diluent directly onto the powder at force, rather than letting it run down the vial wall. This creates unnecessary turbulence.
• Using the wrong diluent volume, resulting in a solution far more or less concentrated than intended, which throws off every dose calculation downstream.
• Skipping refrigeration between doses, even for a few hours on the counter.
• Reusing a vial well past its labeled discard window because it still looks clear.
• Reusing needles across injections from the same vial, which is a needless infection risk with no upside.
• Freezing the reconstituted solution, which most peptide formulations do not tolerate; freezing is a different stress than refrigeration and is not interchangeable with it. None of these mistakes are exotic. They are all avoidable with a written protocol taped to the fridge and a habit of checking the vial before every draw.

Where does tesamorelin reconstitution fit into starting treatment safely?

Reconstitution is a mechanical skill, but it sits inside a bigger decision: whether tesamorelin is right for you at all, and if so, through what route. The approved indication is reduction of excess abdominal fat in HIV-associated lipodystrophy, established through phase 3 randomized controlled trials . Meta-analysis of those RCTs shows measurable visceral adipose tissue reduction with an acceptable safety profile in that population . Use for general fat loss, bodybuilding, or anti-aging in people without HIV-associated lipodystrophy is off-label, meaning outside what the FDA evaluated and approved tesamorelin for, and the evidence base for those uses is far thinner. At Tesamorelin Co we point readers toward provider-reviewed routes precisely because dosing, reconstitution volume, and monitoring should be set by someone who has reviewed your labs and history, not copied from a stranger's forum post. We do not compound or manufacture anything ourselves; we cover the evidence and connect readers to providers and pharmacy partners who handle the clinical and dispensing side correctly. Whatever route you take, get your reconstitution instructions in writing from whoever dispenses your specific product, confirm the diluent, volume, and discard window match that label, and check for tesamorelin peptide side effects before you start, since injection site reactions and other effects were tracked systematically in the original trials .

Frequently asked questions

What do you reconstitute tesamorelin with?

Bacteriostatic water, which is sterile water with 0.9% benzyl alcohol added as a preservative. The benzyl alcohol allows the vial to be used safely across multiple injections rather than requiring same-day discard, which is the main reason it's preferred over plain sterile water for multi-dose peptide vials.

How long does reconstituted tesamorelin last in the fridge?

For the FDA-approved Egrifta product, the labeling specifies use within 24 hours of reconstitution, stored refrigerated at 2°C to 8°C and protected from light. Compounded versions may carry different stated windows from the dispensing pharmacy; always follow the specific product's own label rather than assuming this figure applies universally.

Can you shake tesamorelin to mix it?

No. Shake it and you risk denaturing the peptide, meaning permanently disrupting its molecular structure so it no longer works as intended. Reconstitution should always involve gently swirling the vial in small circles until the powder fully dissolves, never vigorous shaking.

How much bacteriostatic water do you add to tesamorelin?

There's no single universal volume; it depends on the specific vial's peptide content and the concentration you and your provider intend to inject. Always follow the product's own labeling or your prescriber's written instructions rather than a volume you saw used for a different vial strength.

Can you freeze reconstituted tesamorelin?

No. Freezing is a different physical stress than refrigeration and most peptide formulations, including tesamorelin, are not validated as stable once frozen and thawed after reconstitution. Store reconstituted vials refrigerated between 2°C and 8°C, never in the freezer.

How do you know if your tesamorelin vial has degraded?

Check visually before every injection: the solution should stay clear and colorless. Cloudiness, discoloration, or visible particles mean discard it immediately. There's no reliable at-home test for lost potency beyond visual inspection, which is why sticking to the labeled discard window matters even if the vial still looks fine.

Is tesamorelin injected subcutaneously or intramuscularly?

Subcutaneously, meaning into the fat layer just beneath the skin, typically in the abdomen with sites rotated around the navel area. This matches the route used in the phase 3 trials that led to FDA approval for HIV-associated lipodystrophy.

What's the difference between Egrifta and compounded tesamorelin reconstitution?

Egrifta and Egrifta SV are manufactured under FDA oversight with a fixed, tested formulation and a validated 24-hour post-reconstitution stability window. Compounded tesamorelin is prepared under section 503A or 503B of the FDCA using bulk tesamorelin, and its reconstitution volumes and stability claims are set by each individual compounding pharmacy rather than one FDA-reviewed label.

Can you reuse a needle when drawing from a reconstituted tesamorelin vial?

No. Use a new sterile needle for every single injection, even when drawing repeatedly from the same reconstituted vial over several days. Reusing needles raises infection risk for no real benefit and is one of the easiest mistakes to eliminate.

What syringe size should you use for tesamorelin injections?

A fine-gauge insulin syringe, typically 0.5 mL or 1 mL, is standard for accurate small-volume subcutaneous dosing once tesamorelin is reconstituted. A separate, slightly larger syringe (around 3 mL) is used just for drawing up the bacteriostatic water during reconstitution itself.

Does tesamorelin need to be protected from light after mixing?

Yes. Manufacturer labeling for the reconstituted product specifies storage protected from light in addition to refrigeration. Keep the vial in its original carton or wrapped, in the fridge, rather than left exposed on a shelf or counter.

Is tesamorelin reconstitution the same for everyone, regardless of why they're using it?

The mechanics (bacteriostatic water, gentle swirling, refrigeration, discard window) are consistent, but the approved product and its studied regimen apply specifically to HIV-associated lipodystrophy. Use outside that indication is off-label, and dosing volumes should still be set by a provider reviewing your specific product's labeling, not assumed from a general protocol.

Sources

1. PubMed, Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis: The phase 3 trials used a daily reconstituted subcutaneous tesamorelin regimen with tracked safety extension data.
2. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians: Standard peptide reconstitution technique involves bacteriostatic water, gentle mixing rather than shaking, and attention to injection site rotation.
3. PubMed, Tesamorelin (Nature Reviews Drug Discovery, 2011): Tesamorelin is a GHRH analogue developed and approved specifically for HIV-associated lipodystrophy, including the once-daily Egrifta SV formulation.
4. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance: Repeated subcutaneous peptide dosing carries documented risk of local skin reactions at overused injection sites.
5. eCFR, 21 CFR 216.23, the final 503A Bulks List: Bulk drug substances used in 503A compounding, including any applicable tesamorelin listing, are governed by this federal bulks list.
6. eCFR, 21 CFR 216.24, the 503B Bulks List: Outsourcing facilities compounding under 503B must use bulk substances from this separate FDA bulks list.
7. Cornell Law School, 21 U.S.C. 353a, pharmacy compounding: Compounded tesamorelin is prepared under the statutory pharmacy compounding exemption rather than the standard new drug approval pathway.
8. PubMed, Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy: Tesamorelin (Egrifta) is FDA-approved for reduction of excess abdominal fat in HIV-associated lipodystrophy with labeled reconstitution and storage requirements.
9. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin: a meta-analysis of RCTs: Meta-analysis of randomized controlled trials shows measurable visceral adipose tissue reduction with an acceptable safety profile in HIV-associated lipodystrophy.